Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70361 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Noemi Kaetterer und 6 weiteren Autor:innen. Beteiligte Einrichtung: BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Long QT Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
To assess cardiac and safety parameters of iptacopan (an oral, selective, reversible, small‐molecule factor B inhibitor), we conducted a phase I, single ascending dose (SAD), exposure–response study (A2107) instead of a traditional thorough QT study. Healthy participants were randomized 3:1 to receive a single, supratherapeutic, oral dose of iptacopan 400, 800, or 1200 mg, or placebo. A2107's primary objectives were to assess iptacopan's effect on Fridericia‐corrected QT interval (QTcF) in a pooled analysis with the SAD phase of the first‐in‐human X2101 study, and the safety and tolerability of supratherapeutic iptacopan doses in participants. Secondary objectives included pharmacokinetics, changes in selected electrocardiogram (ECG) parameters, and categorical changes to the QTcF, PR, and QRS intervals and heart rate (pooled analysis). Thirty‐two participants were randomized in A2107 and 56 in X2101; demographic data were similar across treatment groups. The estimated placebo‐adjusted change from Day 1 baseline in QTcF at the geometric mean maximum drug concentration was 1.61 (90% confidence intervals: 0.39 to 2.82), 1.26 (−0.42 to 2.94), and 0.84 (−1.54 to 3.22) ms for 400, 800, and 1200 mg doses, respectively. These primary results are consistent with no risk of QT prolongation at single, supratherapeutic, oral iptacopan doses; secondary ECG data support this conclusion. No deaths, serious adverse events (AEs), or AEs leading to study discontinuation were reported; iptacopan was overall well tolerated. A high systemic exposure of iptacopan was confirmed, allowing us to conclude that single, supratherapeutic, oral doses of iptacopan had no QTcF prolongation or proarrhythmic potential in healthy individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
- Novartis BioMedical Research, Cambridge, Massachusetts, USA.
- Novartis Healthcare Private Limited, Hyderabad, India.
- Celerion, Tempe, Arizona, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
ORCID-Profile: Noemi Kaetterer, Kenneth Kulmatycki, Prasanna Kumar Nidamarthy, Robert Schmouder
Zitieren
APA
Kaetterer, N., Kulmatycki, K., Nidamarthy, P. K., McNamara, E., Armas, D., Jarugula, V., & Schmouder, R. (2025). Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals. Clinical and Translational Science. https://doi.org/10.1111/cts.70361
Vancouver
Kaetterer N, Kulmatycki K, Nidamarthy PK, McNamara E, Armas D, Jarugula V, et al. Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals. Clinical and Translational Science. 2025. doi:10.1111/cts.70361
BibTeX
@article{Kaetterer2025,
author = {Kaetterer, Noemi and Kulmatycki, Kenneth and Nidamarthy, Prasanna Kumar and McNamara, Elizabeth and Armas, Danielle and Jarugula, Venkateswar and Schmouder, Robert},
title = {Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70361}
}
EUVIMED